{"id":"ramucirumab-paclitaxel-docetaxel-irinotecan","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Neuropathy (peripheral)"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1743062","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ramucirumab is a monoclonal antibody that binds to VEGF receptor 2 (VEGFR2) on endothelial cells, inhibiting tumor neovascularization and reducing blood supply to tumors. The chemotherapy components (paclitaxel, docetaxel, or irinotecan) work through distinct mechanisms—taxanes stabilize microtubules while irinotecan inhibits topoisomerase I—to directly kill rapidly dividing cancer cells. The combination leverages anti-angiogenic and cytotoxic mechanisms synergistically.","oneSentence":"This is a combination regimen pairing ramucirumab (a VEGF receptor 2 inhibitor) with chemotherapy agents (paclitaxel, docetaxel, or irinotecan) to block tumor angiogenesis while simultaneously attacking cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:12.722Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced gastric cancer or gastroesophageal junction cancer (in combination with chemotherapy)"},{"name":"Non-small cell lung cancer (in combination with chemotherapy)"},{"name":"Colorectal cancer (in combination with chemotherapy)"}]},"trialDetails":[{"nctId":"NCT06346392","phase":"PHASE3","title":"AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-03-04","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":572},{"nctId":"NCT06123494","phase":"PHASE3","title":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-01-09","conditions":"HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","enrollment":360},{"nctId":"NCT05649163","phase":"","title":"Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy","status":"UNKNOWN","sponsor":"Shen Lin","startDate":"2023-01","conditions":"HER2, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma","enrollment":306}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan","genericName":"Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination regimen pairing ramucirumab (a VEGF receptor 2 inhibitor) with chemotherapy agents (paclitaxel, docetaxel, or irinotecan) to block tumor angiogenesis while simultaneously attacking cancer cells. Used for Advanced gastric cancer or gastroesophageal junction cancer (in combination with chemotherapy), Non-small cell lung cancer (in combination with chemotherapy), Colorectal cancer (in combination with chemotherapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}